Condition: Relapsing Multiple SclerosisInterventions: Drug: Interferon beta-1a; Drug: Ocrelizumab-matching placebo; Drug: Ocrelizumab; Drug: Interferon beta-1a-matching placeboSponsor: Hoffmann-La RocheActive, not recruiting Author:
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-RemittingIntervention: Drug: OcrelizumabSponsor: Hoffmann-La RocheActive, not recruiting Author:
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
Condition: Secondary Progressive Multiple SclerosisInterventions: Drug: BAF312; Drug: Baseline disease modifying therapies (DMTs)Sponsor: Novartis PharmaceuticalsActive, not recruiting Author:
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary ProgressiveInterventions: Drug: Ocrelizumab; Other: PlaceboSponsor: Hoffmann-La RocheActive, not recruiting Author:
Multiple Sclerosis-Simvastatin Trial 2
Condition: Secondary Progressive Multiple Sclerosis (SPMS)Interventions: Drug: Simvastatin; Drug: PlaceboSponsors: University College, London; University of Edinburgh; Queen Mary University of London; London School of Hygiene and Tropical Medicine; University of Leeds; The Leeds Teaching Hospitals NHS Trust; Imperial College Healthcare NHS TrustActive, not recruiting Author:
Impact of Core Performance on Functional Parameters in Multiple Sclerosis
Condition: Multiple SclerosisIntervention: Other: AssessmentSponsor: Istanbul University-CerrahpasaCompleted Author:
Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis
Condition: Multiple SclerosisInterventions: Drug: temelimab 18 mg/kg; Drug: temelimab 36 mg/kg; Drug: temelimab 54 mg/kg; Drug: PlaceboSponsor: GeNeuro Innovation SASCompleted Author:
Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility
Condition: Multiple SclerosisIntervention: Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)Completed Author:
Normobaric Hypoxic Training and Multiple Sclerosis
Condition: Multiple SclerosisInterventions: Other: Hypoxic training; Other: Normoxic trainingSponsor: Charite University, Berlin, GermanyCompleted Author:
Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis
Condition: Multiple SclerosisIntervention: Drug: Mangafodipir (Teslascan)Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)Completed Author:
Sensory Integration Disorders in Patients With MS Including Disease Advancement and Relapses in the Last Year
Condition: Multiple SclerosisIntervention: Diagnostic Test: Scale for the Assessment of Sensory Integration in AdultsSponsor: Pomeranian Medical University SzczecinCompleted Author:
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis; Exercise Program; Telerehabilitation; Autoimmune DisorderInterventions: Other: Fatigue Severity Scale; Other: Berg Balance Test; Other: Time up and go- 25 steps walking test; Other: Multiple Sclerosis Quality of Life; Other: Brief International Cognitive Assessment for MS (BICAMS); Other: Beck Depression and Anxiety ScaleSponsor: Muğla Sıtkı Koçman UniversityCompleted Author: